Compare · KNSA vs RVPH
KNSA vs RVPH
Side-by-side comparison of Kiniksa Pharmaceuticals International plc (KNSA) and Reviva Pharmaceuticals Holdings Inc. (RVPH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both KNSA and RVPH operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- KNSA is the larger of the two at $6.24B, about 1382.8x RVPH ($4.5M).
- Both names hit the wire about 1 times in the past 4 weeks.
- KNSA has more recent analyst coverage (7 ratings vs 6 for RVPH).
- Company
- Kiniksa Pharmaceuticals International plc
- Reviva Pharmaceuticals Holdings Inc.
- Price
- -
- -
- Market cap
- $6.24B
- $4.5M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- 2020
- News (4w)
- 1
- 1
- Recent ratings
- 7
- 6
Kiniksa Pharmaceuticals International plc
Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its product candidates include Rilonacept, which is in Phase III clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody that is in Phase II clinical trials for the treatment of giant cell arteritis; and Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition. The company's preclinical product candidates comprise KPL-404, a monoclonal antibody inhibitor of the CD40/CD40L interaction, a central control node of T-cell-dependent, and B-cell-mediated humoral adaptive immunity. The company has a clinical collaboration with Kite Pharma, Inc. to evaluate the combination of Yescarta and Mavrilimumab in patients with relapsed or refractory Large B-Cell lymphoma. Kiniksa Pharmaceuticals, Ltd. was founded in 2015 and is based in Hamilton, Bermuda.
Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. Its lead product candidate is RP5063 that has completed Phase II clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials for treating bipolar disorder, major depressive disorder, behavioral and psychotic symptoms, dementia or Alzheimer's disease, parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis; and RP1208 that has completed pre-clinical development studies for the treatment of depression and obesity. The company is based in Cupertino, California.
Latest KNSA
- Wells Fargo initiated coverage on Kiniksa Pharmaceuticals with a new price target
- Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference
- CHIEF FINANCIAL OFFICER Ragosa Mark covered exercise/tax liability with 4,404 units of Class A Ordinary Share and converted options into 9,104 units of Class A Ordinary Share, increasing direct ownership by 29% to 20,854 units (SEC Form 4)
- CHAIRMAN & CEO Patel Sanj K converted options into 31,318 units of Class A Ordinary Share and covered exercise/tax liability with 15,144 units of Class A Ordinary Share (SEC Form 4)
- CHIEF MEDICAL OFFICER Paolini John F. converted options into 8,328 units of Class A Ordinary Share and covered exercise/tax liability with 4,029 units of Class A Ordinary Share, increasing direct ownership by 7% to 69,922 units (SEC Form 4)
- CHAIRMAN & CEO Patel Sanj K converted options into 31,318 units of Class A Ordinary Share and covered exercise/tax liability with 15,144 units of Class A Ordinary Share (SEC Form 4)
- CHIEF OPERATING OFFICER Moat Ross converted options into 8,285 units of Class A Ordinary Share and covered exercise/tax liability with 4,007 units of Class A Ordinary Share, increasing direct ownership by 36% to 16,307 units (SEC Form 4)
- CHIEF ACCOUNTING OFFICER Megna Michael R converted options into 11,496 units of Class A Ordinary Share, covered exercise/tax liability with 5,531 units of Class A Ordinary Share, sold $369,380 worth of Class A Ordinary Share (4,600 units at $80.30) as part of a pre-agreed trading plan and was granted 279 units of Class A Ordinary Share, increasing direct ownership by 6% to 29,062 units (SEC Form 4)
- SEC Form 144 filed by Kiniksa Pharmaceuticals International plc
- Director Quart Barry D gifted 2,600 units of Class A Ordinary Share, decreasing direct ownership by 17% to 12,745 units (SEC Form 4)
Latest RVPH
- Reviva to Participate in the Lytham Partners Fall 2026 Investor Conference
- Amendment: SEC Form SCHEDULE 13G/A filed by Reviva Pharmaceuticals Holdings Inc.
- SEC Form 10-Q filed by Reviva Pharmaceuticals Holdings Inc.
- Reviva Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Reviva Reports Second Quarter 2026 Financial Results and Recent Business Highlights
- Amendment: SEC Form SCHEDULE 13G/A filed by Reviva Pharmaceuticals Holdings Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Reviva Pharmaceuticals Holdings Inc.
- SEC Form 25-NSE filed by Reviva Pharmaceuticals Holdings Inc.
- Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing
- Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th